NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two...
Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Natura: | Articolo |
Lingua: | English |
Pubblicazione: |
Nature Portfolio
2018-01-01
|
Serie: | Nature Communications |
Accesso online: | https://doi.org/10.1038/s41467-017-02672-0 |